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The molecular pathogenic mechanisms of prion diseases are far from clear. Genomic analyses have revealed
genetic biomarkers potentially involved in prion neuropathology in naturally scrapie-infected sheep, a good animal
model of infectious prionopathies. However, these biomarkers must be validated in independent studies at different
stages of the disease. The gene and protein expression profiles and protein distribution of six potential genetic
biomarkers (i.e., CAPN6, COL1A2, COL3A1, GALA1, MT2A and MTNR1B) are presented here for both the early and
terminal stages of scrapie in five different brain regions. Gene transcription changes were confirmed in the medulla
oblongata, and the expression profiles were generally similar in other central nervous system regions. The changes
were more substantial in clinical animals compared to preclinical animals. The expression of the CAPN6 protein
increased in the spinal cord and cerebellum of the clinical and preclinical brains. The distribution of the GALA1 was
identified in glial cells from the cerebellum of scrapie-infected animals, GALA1 protein expression was increased in
clinical animals in the majority of regions, and the increase of MT2A was in agreement with previous reports. The
downregulation of MTNR1B was especially marked in the Purkinje cells. Finally, although collagen genes were
downregulated the protein immunostaining did not reveal significant changes between the scrapie-infected and
control animals. In conclusion, this study of gene transcription and protein expression and distribution confirm
CAPN6, GALA1, MTNR1B and MT2A as potential targets for further prion disease research.Introduction
Transmissible spongiform encephalopathies (TSE), or
prion diseases, are a group of fatal neurodegenerative
disorders of sporadic, genetic or infectious origin [1].
This group of disorders includes Creutzfeldt–Jakob
disease (CJD), Gerstmann-Sträussler-Scheinker disease,
kuru and fatal familial insomnia in men [2-4], scrapie in
sheep and goats [5] and bovine spongiform encephalo-
pathy (BSE) in cattle [6]. There is compelling evidence
[7] that, according to the “protein-only” hypothesis [8],
TSE are caused by the conversion of normal mammalian
prion protein (PrPc) into its pathological conformation,
or scrapie-associated prion protein (PrPSc), which is* Correspondence: rbolea@unizar.es
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reproduction in any medium, provided the orabnormally folded, β-sheet enriched and protease re-
sistant [9]. The accumulation of PrPSc in the central
nervous system (CNS) induces neurodegeneration,
spongiosis and glial cell activation and death [1,8,10,11].
Prions are naturally infectious by the oral route and can
be transmitted experimentally by inoculation. However,
the long incubation period of these diseases has slowed
the progress of research investigation.
Classical scrapie in sheep is the earliest known
prionopathy. The first descriptions date back to 1732
[12], and infected animals are considered to be a good
animal model of the infectious prion diseases. To under-
stand the pathogenesis of scrapie and other prion dis-
eases, a large number of studies have been performed,
including the analysis of gene and protein expression in
both the early and terminal stages of the disease [13-19].
This research is of critical importance to identify notd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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targets of this incurable group of diseases.
We recently published [20] the gene transcription pro-
files from the medulla oblongata of sheep, which were
naturally infected with clinical scrapie, using a micro-
array platform. In this study, criteria based on fold-
change values, gene ontology and association analyses
with PrPSc deposition, astrocytosis and spongiosis were
used to select a set of neuropathology-related genes that
had previously been reported to be associated with prion
and other neurodegenerative diseases in experimental
models [21-26]. The gene transcription results were con-
firmed by quantitative Real Time PCR (qRT-PCR) using
the same animals that were included in the microarray
study. The gene transcription data can yield relevant in-
formation regarding ongoing processes in the diseased
brain, but the role of each individual gene requires fur-
ther investigation. An evaluation of whether the gene
transcription changes reflect the levels of the end-
product of each gene (i.e., the protein itself ), and the de-
termination of the cellular locations of these proteins
may help to elucidate the biological relevance of the dif-
ferential gene transcription observed between healthy
and scrapie-infected sheep.
In the present study, in the medulla oblongata of a lar-
ger set of clinical naturally infected sheep, we confirm
the differential expression of the six genes that displayed
the largest up- or down-regulation in our previous work
[20]: three upregulated (i.e., calpain 6 [CAPN6], galanin
1 [GALA1] and methallothionein 2A [MT2A]) and three
downregulated genes (i.e., collagen 1 alpha 2 [COL1A2],
collagen 3 alpha 1 [COL3A1] and melatonin receptor 1b
[MTNR1B]). We also extended the analysis to include
gene transcription data from three additional CNS re-
gions. In addition, we evaluated whether these changes
are present in the preclinical stages of the disease. Fi-
nally, for the first time, we report the distribution of the
encoded proteins in different regions of the CNS of both
clinical and preclinical field cases of ovine scrapie.
Materials and methods
Ethics statement
This study was approved by the Ethics Committee for
Animal Experiments of the University of Zaragoza (Permit
Number: PI02/08) and was carried out in strict accor-
dance with the recommendations for the care and use of
experimental animals and in agreement with the national
law (R.D. 1201/2005).
Animals
Scrapie animals obtained from scrapie-infected flocks
from several geographical regions were maintained for
research purposes at our research center. The animalswere genotyped for PRNP polymorphisms. The complete
PRNP gene open reading frame was sequenced as pre-
viously described [27], and the sheep with the ARQ/ARQ
genotype were chosen for this study. None of the selected
animals bore additional polymorphisms in the fragment
analyzed. The animals were free from the Brucella and
Maedi-Visna viruses, were periodically vaccinated against
enterotoxemia caused by Clostridium perfringens and
were subjected to an antiparasitic treatment.
A total of 28 Rasa Aragonesa female sheep (infected
and control group, aged 1–10 years) were included in
this study (Table 1). In order to have specific comparison
within groups, most of the scrapie infected animals were
in the range of age of controls. For the gene transcrip-
tion studies in different brain regions, 26 animals were
used: 11 healthy control sheep, 10 sheep at the terminal
stage of natural scrapie infection and 5 sheep with no
clinical signs of infection (preclinical stage). Seventeen
sheep were used for the protein immunodetection study:
healthy control animals (n = 6), animals at the terminal
stage of natural scrapie infection (n = 7) and a group of
preclinical animals (n = 4). For the protein blotting as-
says, 12 animals were used divided into the three groups
(healthy control, preclinical and clinical terminal stage
animals), each group containing 4 animals. Table 1
shows the number and characteristics of the animals
used in each study.
The diagnosis of scrapie for clinical sheep was
performed by describing the clinical signs associated
with the disease [28]. The diagnosis of scrapie for clin-
ical and preclinical animals was made by third eyelid
[28] and rectal mucosa biopsies [29] and was confirmed
in the medulla oblongata from the brain stem using a
rapid test (Bio-Rad TeSeE) and immunohistochemistry
to detect PrPSc using the 6H4 monoclonal antibody [30].
The control animals were matched for age, breed, sex
and genotype and were selected from flocks belonging
to scrapie-free regions. The third eyelid biopsy was car-
ried out in all of the animals that were included in the
study. The absence of PrPSc was also confirmed in the
medulla oblongata, cerebellum, mesencephalon, thal-
amus, hypothalamus and frontal cortex by immunohisto-
chemical methods (with the L42 antibody, described in
the immunohistochemistry section) and by Western
blotting (PrionicsW-Check WESTERN).
Necropsy and tissue collection
Necropsy was performed immediately after the animals
were sacrificed by an intravenous injection of sodium
pentobarbital and exsanguination. The postmortem
examination of the animals did not reveal additional
pathological findings. The tissue samples were rapidly
preserved and processed according to the established
Table 1 Details of the analyzed animals used in
immunohistochemistry (IHC), quantitative real-time PCR







Ctrl1 6.5 Ctrl ✓ ✓ -
Ctrl2 6 Ctrl ✓ ✓ -
Ctrl3 9 Ctrl ✓ ✓ ✓
Ctrl4 10 Ctrl ✓ ✓ ✓
Ctrl5 3 Ctrl ✓ ✓ ✓
Ctrl6 5.5 Ctrl ✓ ✓ ✓
Ctrl7 4.5 Ctrl - ✓ -
Ctrl8 4.5 Ctrl - ✓ -
Ctrl9 4.5 Ctrl - ✓ -
Ctrl10 1.5 Ctrl - ✓ -
Ctrl11 2.5 Ctrl - ✓ -
SC1 3.5 PC ✓ ✓ ✓
SC2 1.5 PC ✓ ✓ ✓
SC3 4.5 PC ✓ ✓ ✓
SC4 1 PC ✓ ✓ ✓
SC5 1.5 PC - ✓ -
SC6 5.5 C ✓ - -
SC7 6.5 C ✓ - -
SC8 5 C ✓ ✓ -
SC9 2.5 C ✓ ✓ ✓
SC10 4 C ✓ ✓ ✓
SC11 5.6 C ✓ ✓ ✓
SC12 7 C ✓ ✓ ✓
SC13 3.5 C - ✓ -
SC14 4 C - ✓ -
SC15 4.5 C - ✓ -
SC16 4 C - ✓ -
SC17 2 C - ✓ -
Clinical status of each animal is described: control (Ctrl), preclinical (PC) or
clinical (C).
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vided into two halves, one of which was snap-frozen in
liquid nitrogen prior to long-term storage at -80°C until
RNA and protein extraction; the other half was fixed in
10% neutral-buffered formalin for 10 days, post-fixed
and paraffin-embedded according to standard proce-
dures for histopathological and immunohistochemical
analysis. Later, the brains were dissected to isolate the
most relevant neuropathological tissues, including the
cervical spinal cord (cSc), medulla oblongata (Mobl),
cerebellar cortex (Cc), thalamus (T) and hypothalamus
(Ht). When the thalamus and hypothalamus are evalu-
ated together, they are referred to as the diencephalon
(Dien).Total RNA isolation and cDNA synthesis
Total RNA was isolated from Tissuemizer-disrupted cSc,
Mobl, Cc and Dien using the RNeasy Mini Kit (Qiagen,
Crawley, UK) according to the manufacturer’s instruc-
tions. To avoid genomic DNA contamination, the tissue
samples were treated for 25 min at 37°C with two units
of TURBO DNase (Ambion, Austin, TX, USA). The
quality of the total RNA was assessed based on the pre-
sence of distinct intact 28S and 18S ribosomal RNA
bands in an electrophoresis gel. The RNA concentration
was determined by OD (260/280) using a Nanodrop
spectrophotometer (UV spectrophotometer Q3000,
Quawell Technology, Inc., USA). The complementary
DNA (cDNA) was synthesized from 1 μg of RNA using
random hexamers with the Superscript First Standard
Synthesis System for RT-PCR (Invitrogen). To confirm
the elimination of the genomic DNA, reverse transcrip-
tion reactions were performed with and without the
enzyme.
Quantitative real-time PCR
Quantitative real-time PCR was performed to determine
the expression of 6 genes (i.e., CAPN6, COL1A2,
COL3A1, GALA1, MTNR1B and MT2A) in the four re-
gions of study. The PCR primer sequences used for the
quantification of the gene transcription have been previ-
ously described [20]. To improve the normalization ac-
curacy, the geometric mean of three housekeeping genes
was used to calculate a normalization factor (NF), which
was used to normalize the expression level for each gene
for each sample [31]. The NF was calculated from
GAPDH, G6PDH and RPL32 expression data. These are
the three most stable reference housekeeping genes in
the sheep medulla oblongata and have been used as in-
ternal references in previous expression studies of scra-
pie infection [32]. The primers and PCR conditions for
the amplification of these housekeeping genes have been
described previously [32,33].
The qRT-PCR method was performed using SYBRW
Green (PE Applied Biosystems) assays. The PCR amplifi-
cation was performed in an ABI-Prism Fast 7500 Se-
quence Detection System (PE Applied Biosystems). All
qRT-PCR reactions were run in triplicate with 10-20 ng
of cDNA as the template and a 300-nM final primer
concentration in a total reaction volume of 10 μL. The
universal conditions were used with an initial 10 min
activation and denaturation step at 95°C, followed by 40
cycles of 15 s at 95°C and 30 s at 60°C. A dissociation
curve protocol was used after each qRT-PCR reaction to
identify the presence of nonspecific PCR bands or high
levels of primer dimers. The baseline and threshold for
the Ct calculations were set automatically with the ABI-
Prism 7500 software, version 2.0.1, and the levels of gene
transcription were determined using the comparative Ct
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differences observed between the groups were statisti-
cally significant (*P < 0.05 and **P < 0.01).
Histopathology
After tissue fixation, the brain slices (4 mm) were
immersed in 98% formic acid for 1 h to reduce prion in-
fectivity. The tissues were then embedded in paraffin
wax. The sections (4 μm) were stained with hematoxylin
and eosin (HE) to evaluate the morphological changes.
Additional sections were mounted on glass slides treated
with triethoxysilyl propylamine for subsequent immuno-
histochemical procedures.
The brain structures analyzed in this study included
the thalamus (T), hypothalamus (Ht), medulla oblongata
(Mob), cervical spinal cord (cSc) and cerebellar cortex (Cc).
Immunohistochemistry
PrPSc immunohistochemistry (IHC) in the five selected
regions was performed as previously described [34].
Briefly, pre-treatment included immersion in formic acid
for 15 min, treatment with proteinase K (4 μg/mL;
Roche, Switzerland) for 15 min at 37°C and hydrated
autoclaving. Monoclonal antibody L42 (1:500 dilution
for 30 min; R-Biopharm, Germany) served as the pri-
mary antibody, EnVision™ (DAKO, Denmark) was uti-
lized for visualization and 3,3’-diaminobenzidine (DAB)
was used as the chromogen. In each case, pre-treatment
before the application of these reagents involved heat-
induced epitope retrieval with citrate buffer (pH 6.0).
Astrocytosis was evaluated based on glial fibrillary
acidic protein (GFAP) immunostaining, as previously de-
scribed [11,35]. Briefly, after heat-induced epitope re-
trieval pretreatment with citrate buffer (pH 6.0), the
sections were incubated for 1 h at RT with rabbit poly-
clonal anti-GFAP antibody (1:400 dilution; DAKO). In
routine immunoreactions, the omission of the primary
antibodies in the control and scrapie slides served as
negative controls.
Proteins encoded by the three upregulated genes
(CAPN6, GALA1 andMT2A) and the three downregulated
genes (COL1A2, COL3A1 and MTNR1B) were studied. To
analyze the expression and distribution of these proteins,
formalin-fixed, paraffin-embedded CNS tissue sections
from the preclinical, clinical and control animals were
studied by immunohistochemistry and were processed in a
different manner for the different markers. The specificity
for the ovine protein of interest was initially checked on
the target ovine tissues with the chosen, commercially
available antibodies. The optimal technical specifications
for each antibody in ovine tissue are summarized in
Table 2. The visualization system used was a 30 min incu-
bation with a polymer linked to peroxidase and either anti
mouse or anti rabbit immunoglobulin (EnVision, DAKO)followed by immersion in a 3,3’-diaminobenzidine solution
with 0.05% hydrogen peroxide. Omission of the primary
antibody was used as a control for nonspecific staining.
The positive control tissues used for each antibody are
specified in Table 2.
The immunostained sections were examined with a
NIKON Eclipse 90i optical microscope. The immuno-
labeling patterns on ovine brain tissue were described, and
a semi-quantitative analysis of the immunolabeling inten-
sity was performed. Immunolabeling scores, ranging from
0 (absence of immunolabeling) to 1 (mild), 2 (moderate),
3 (intense) and 4 (maximum intensity), were assigned to
each brain region (i.e., cSc, Mobl, Cc, T and Ht). Each area
was investigated as a global region for scoring. For the
statistical analysis, the Mann Whitney test was applied
(**P < 0.05 with a 95% confidence interval and *P < 0.1
with 90% confidence interval).
Protein extraction and Western/dot blot analysis
In the four analyzed regions, at least 0.5 g of the brain
frozen sections were homogenized in 5 mL of PrionicsW
Check Western homogenization buffer (Prionics AG,
Zurich, Switzerland) and centrifuged at 10 000 × g for
10 min at 4°C. Supernatants containing total protein ex-
tracts were recovered and protein concentrations were
measured by BCA (bicinchoninic acid) protein assay
(Sigma-Aldrich, St. Louis, MO, USA). For Western-blot,
after denaturation at 95 °C for 5 min, protein extracts
(100 μg of total protein) were subjected to SDS/PAGE
(12% and 8% polyacrylamide) at 150 V for 45 min and
transferred to PVDF membranes (Bio-Rad, Hercules,
CA, USA) at 200 V for 1 h using a Mini-PROTEAN 3
system (Bio-Rad, Hercules, CA, USA). For the dot blot
technique, 30 μg of total protein were deposited in du-
plicate over the PVDF membranes.
The PVDF membranes were treated with blocking so-
lution (TBS buffer, 0.5% Tween 20 and 5% non-fat milk)
for 1 h at RT (Room Temperature), and then incubated
for 1 h with the appropriate primary antibody diluted in
blocking buffer. The primary antibodies used for im-
munoblotting assays were the same used in IHC staining
experiments (Table 2). Next, the membranes were
incubated for 1 h with HRP-conjugated secondary anti-
body diluted 1:3500 in blocking buffer (goat anti-mouse
IgG-HRP for anti-COL1A2 and anti-MT2A or goat anti-
rabbit IgG-HRP for anti-CAPN6, anti-COL3A1, anti-
GALA1 and anti-MTNR1B; Santa Cruz Biotechnology).
Three washes 10 min each with TBS-0.5% Tween 20
were performed between incubation periods. Western/
dot blots were developed using an ECL + reagent kit
(Amersham-GE Healthcare) and visualized with a Bio-
Rad VersaDoc imaging system. For the purpose of these
studies, blots were imaged following exposure for 10
min (enhanced images) to ensure that samples








Dilution epitope retrieval Visualization
system
Positive control Dilution


























mild staining of trabeculae).
1: 5000
GALA1 galanin 1 Rabbit polyclonal
ENZO Life sciences
BML-GA1161-0100
1:400 Brain tissue (stains diffusely







1:100 Retina (stains the plexiform
layers).
1:1500
CAPN6 calpain 6 Rabbit polyclonal
Abcam AB76974
1:50 HIER Citrate buffer pH 6

















Brain tissue (stains stellate
shaped glial cells).
1:1500
Filali et al. Veterinary Research 2013, 44:14 Page 5 of 17
http://www.veterinaryresearch.org/content/44/1/14containing comparatively low protein concentrations
were detectable.
Western blot results were used to determine the specifi-
city of the used antibodies. The quantification analysis was
performed based on the dot blot results using the ImageJ
1.4.3.67 image-analysis software package (Psion Image,
NIH) following a simple method of analysis, performed by
integrating the grey levels of pixels (volume) surrounded
by a circular selection. This method is described on the
ImageJ website [36]. Density of immunoreactive dots was
normalized for Ponceau Red and is reported as arbitrary
units (a.u.). Data are expressed as means ± standard error.
A Student’s t test was used to determine if the differences
observed between the groups were statistically significant
(*P < 0.05 and **P < 0.01).Results
Scrapie-associated neuropathology
Prionopathy associated spongiosis, PrPSc deposition and
gliosis (assessed by GFAP immunoreactivity) were evalu-
ated semiquantitatively in the four analyzed brain regions
(cSc, Mobl, Cc and Dien) from 6 controls, 4 preclinical
and 7 clinical scrapie-infected sheep (Figure 1). The distri-
bution of these markers was consistent with most of the
features previously described for classical scrapie [18].
Despite the high variability observed for all markers within
the scrapie groups, in most cases, statistically significant
differences were recorded between these animals and the
control group (P < 0.05).PrPSc deposition and spongiform degeneration were
detected only in the infected animals, and the absence of
PrPSc was characteristic of the control group. Regarding
the clinical animals, intraneuronal and neuropil PrPSc
immunolabeling was strong in cSc and Mobl, and mod-
erate in Cc and Dien, which was in accordance with
classical scrapie infected sheep. In preclinical animals,
PrPSc deposits were moderate in Sc and Mobl and weak
in Cc and Dien, showing a similar distribution to that
of clinical sheep. In summary, the presence of PrPSc
and spongiform degeneration was lower in preclinical
than in clinical sheep. The evaluation of haematoxylin-
eosin-stained sections revealed a significant and moder-
ate to weak increase of spongiosis in the Mobl, Cc, cSc
and Dien of the preclinical group (Figure 1). Spongiosis
was also shown in the animals with a clinical state of
scrapie, in which the lesion was significantly stronger in
the Dien following by Mobl and cSc. The spongiosis
scores were moderate in the Cc of clinical animals com-
pared with controls.
A generalized increase of astroglial marker glial fibrillary
acidic protein (GFAP) immunostaining was observed in
the brains of the scrapie-infected sheep. Hyperplasia and
hypertrophy of the stellate GFAP-positive cells, consistent
with reactive astrocytosis, was observed in all analyzed
brain regions. For the clinical group, the Dien and cSc sec-
tions evaluated show higher scores, followed by moderate
scores in Mobl and Cc. Regarding the preclinical group,
only Mobl and Dien show a moderate and significant in-





















































Figure 1 Semi quantitative assessment values of PrPSc
deposition, spongiform degeneration and glial fibrillary acidic
protein expression as a marker for astrocytes in the spinal
cord, medulla oblongata, cerebellum and diencephalon of
control (white bars), preclinical (grey bars) and clinical (black
bars) scrapie sheep evaluated (from 0: negative, to 4: lesion/
staining present at maximum intensity). Significant differences
were determined using the Mann Whitney test (**P< 0.05 and *P< 0.1).
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The expression of the six genes was analyzed in four dif-
ferent regions of the central nervous system (i.e., the
cSc, Mobl, Cc and Dien) in the clinical and preclinical
scrapie-infected and control sheep. As shown in Figure 2,
we confirmed the overexpression of CAPN6, GALA1
and MT2A in the medulla oblongata in clinical stage
scrapie-infected animals, as well as the downregulation
of COL1A2, COL3A1 and MTNR1B. In general, this pro-
file was maintained in the other CNS regions of clinical
sheep. Upregulation of GALA1 was notable in the cer-
vical spinal cord and the cerebellum (8- and 12-fold
change [FC], respectively) and, to a lesser degree (4-FC),
in the diencephalon. A significant increase of MT2A and
CAPN6 (2-4-FC) was observed in all the analyzed brain
regions; and a 5-fold decrease of MTNR1B was observed
in the cerebellum. Although a trend of COL1A2 and
COL3A1 downregulation was observed in all brain re-
gions, their expression levels were only significantly dif-
ferent from controls in the medulla oblongata.
In contrast, the preclinical animals did not present sig-
nificant changes with respect to controls in most cases.
However, the upregulation observed for CAPN6 and
MT2A in the clinical animals was also observed in the
preclinical spinal cords and cerebellar cortex, and the
downregulation of MTNR1B was also evidenced in the
preclinical cerebellar cortex. In contrast, CAPN6 in the
medulla oblongata displayed opposite and significant
(p < 0.05) gene transcription profiles compared to those
observed in the clinical phases of the disease.
Protein distribution in central nervous system
Regarding immunohistochemical markers, the first obs-
tacle that needed to be overcome was the lack of com-
mercially available ovine-specific antibodies against most
of the selected genes and the lack of previously pub-
lished information on the immunolabeling that should
be expected for such markers in the adult ovine CNS. A
number of combinations of epitope retrieval treatment
and antibody dilution were tested to determine the opti-
mal immunostaining procedures.
A detailed description of the immunostaining pattern
for each antibody is provided because no previous data,
to the authors’ knowledge, has been published on the
immunolabeling of the proposed markers in the ovine
CNS, except for MT1 + 2 [11].
Collagen 1 alpha 2 immunolabeling
In the ovine skin samples, the antibody against COL1A2
stained the subepithelial connective tissue and, in the
spleen, a mild perivascular signaling as well as in the
capsule was observed but the trabeculae were negative.
COL1A2 staining in the CNS was confined to lepto-
meningeal and perivascular cells but was very mild or
Figure 2 Gene transcription profiles of six scrapie-related genes (i.e., CAPN6, COL1A2, COL3A1, GALA1, MTNR1B and MT2A) in four CNS
regions in control (white bars), preclinical scrapie (grey bars) and clinical scrapie (black bars) sheep in the cervical spinal cord, medulla
oblongata, cerebellar cortex and diencephalon. Differences between groups were analyzed using a Student’s t-test *P < 0.05 and **P < 0.01).
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vessels (Figure 3A and B). No significant differences
were observed when comparing the control and scrapie-
infected animals.
Collagen 3 alpha 1 immunolabeling
In the ovine skin samples, COL3A1 antibody stained the
subepithelial connective tissue and, in the spleen, a mild
perivascular immunostaining as well as in the trabeculae
was observed, but the capsule was negative.
In the CNS, perivascular labeling corresponding to the
basement membrane of blood vessels was observed. The
amount of stained intraparenquimatous blood vessels
was slightly higher in the cervical spinal cord compared
to other brain regions studied. Additionally, the lepto-
meninges were labeled with the COL3A1 antibody
(Figure 3C and D). Again, no significant differences were
observed between the control and scrapie-infected
animals.
Galanin 1 immunolabeling
A punctiform, synaptic-like immunostaining was ob-
served in several regions, such as the nucleus of the soli-
tary tract in the medulla oblongata, which occasionallydisplayed a perineuronal arrangement (Figure 4A), or in
the substantia gelatinosa (Figure 4C) in the dorsal horn
of the cervical spinal cord. In addition, multiple cells
exhibited intracytoplasmic immunolabeling, particularly
in the hypothalamus, but also in the cerebellar cortex,
thalamus, mesencephalon and medulla oblongata
(Figure 4E). The region postrema was strongly stained
(Figure 4F). The immunostaining in the cerebral cortices
was minimal. Some of the stained cells could clearly be
identified morphologically as glial cells, either oligoden-
drocytes (Figure 4B) or astrocytes (Figure 4D), while the
majority of the cells were identified as medium- to
small-sized neurons. Occasionally, punctiform intracy-
toplasmic immunostaining was observed in larger neu-
rons, such as the motor neurons of the cervical spinal
cord’s ventral horn. In the cerebellum, these small, posi-
tively stained cells were located mainly in the Purkinje
cell layer, around the piriform neurons, which occasio-
nally had neurites decorated with punctiform immu-
nolabeling (Figure 4I).
When comparing the uninfected animals with those
infected with scrapie, minimal differences were observed.
Increased immunolabeling was noticed in the scrapie-
infected sheep, particularly in the medulla oblongata and
Figure 3 Immunostaining patterns of COL1A2 (A and B) and COL3A1 (C and D). COL1A2 perivascular staining in the meninges (A) as well
as leptomeningeal cells (arrowheads in B). COL3A1 stained medium sized blood vessel walls within the nervous parenchima (C) as well as
leptomeningeal cells (arrowheads in D) and meningeal blood vessels (D).
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immunostaining of glial-shaped cells (Figure 4H and J).
Semiquantitative evaluation of the signaling yielded sta-
tistically significant differences between the preclinical
and clinical groups in the cerebellum.Calpain 6 immunolabeling
Sheep placental tissue was successfully stained (Figure 5A)
and included in the experiment as a positive control
because CAPN6 expression has been described in the pla-
cental epithelium in other species [37]. CAPN6 immuno-
staining of the sheep brain parenchyma consisted of a
moderate diffuse neuropil staining that was more intense
in some of the brain regions studied, such as the molecu-
lar layer of the cerebellum (Figure 5B), the substantia
gelatinosa of the dorsal horn of the cervical spinal cord
and the medulla oblongata. The neuronal cytoplasm was
generally unstained, but the nuclei were positive (exclu-
ding the nucleolus) (Figure 5D). In addition, strong glial
cell staining was observed in the white matter, primarily in
the nucleus but also in the cytoplasm (Figure 5C).
The variability observed between different individuals
upon quantification was considerable. However, both
scrapie-infected groups tended to show higher scores in
the cerebellum, medulla oblongata and cervical spinal
cord. This increase was statistically significant when the
cervical spinal cord score was compared between the
control and clinical scrapie groups (Figure 6).Melatonin receptor 1B immunolabeling
The ovine retina was used as a positive immunohisto-
chemical control. In this tissue, both the external and in-
ternal plexiform layers were stained positively by the
antibody against MTNR1B. In the CNS, a mild, diffuse
neuropil staining was observed in the gray matter, but
the white matter was negative. This staining was particu-
larly intense in the dorsal horn of the cervical spinal
cord. In the cerebellar cortex, the Purkinje cell dendrites
were occasionally observed with intense cytoplasmic
immunolabeling (Figure 7C).
When the control animals were compared to the
scrapie-infected animals, no significant differences were
observed regarding MTNR1B immunostaining in any of
the CNS regions studied, with the exception of the cere-
bellum (Figure 7C and D). A significant reduction of the
Purkinje cell dendrite staining was noticed between the
control and preclinical sheep (P < 0.1) and between the
control and clinical sheep (P < 0.05) (Figure 6). The me-
dulla oblongata also showed a stronger staining intensity
in the controls compared to the scrapie-infected animals;
however, the limited availability of this region for immu-
nohistochemical studies precluded statistical significance
(Figure 7A and B).Metallothionein 1 + 2 immunolabeling
The specific immunolabeling patterns of MT1 + 2 anti-
bodies in the sheep brain have been published [11].
Figure 4 (See legend on next page.)
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Figure 4 GALA1 patterns. Galanin immunostaining patterns in different CNS regions of control animals (A to F). (A) Synaptic like
punctiform pattern in the medulla oblongata, note the perineuronal arrangement (arrowhead). (B) Cytoplasmic immunostaining of
oligodendrocyte rows in the cerebellar white matter (arrowheads). (C) Synaptic pattern in the cervical spinal cord dorsal horn (Substantia
gelatinosa). (D) Cytoplasmatic immunostaining of astrocytes in the mesencephalon. (E) Intracytoplasmic immunostaining in multiple cells in the
Thalamus, either glial cells or small neurons. (F) The neurons and glial cells in the area postrema are strongly immunostained. (G) GALA1
immunolabeling in the medulla oblongata in the control animals (H) clinical scrapie-infected animals. (I) GALA1 immunolabeling in the cerebellar
cortex in the control animals (J) clinical scrapie-infected animals. GALA1 immunolabeling was slightly more intense in the cerebellar cortex on the
clinical scrapie-infected sheep compared to the control. The remaining regions show little variation.
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served in all studied brain regions.
A semiquantitative analysis shows statistically signifi-
cant higher scores in scrapie-infected animals in almost
all the regions evaluated when compared to the control
group. Differences were also observed between the clin-
ical and preclinical groups, particularly in the thalamus
and cerebellum (Figure 6).Figure 5 CAPN6 immunostaining. (A) Staining of the sheep placental ep
moderate, diffuse neuropil staining of the gray matter of the molecular lay
matter, the glial cells were strongly immunolabeled. Mainly, it consisted of
(arrowhead). (D) Ventral horn of cervical spinal cord: Intranuclear staining w
case in which staining was stronger than in the (F) same region of a contrProtein quantification by blotting assay
For the immunoblotting assays and in order to deter-
mine the optimal procedures, many dilution combina-
tions of the primary and secondary antibodies were
tested. Western blot results displayed low band inten-
sities, meaning low expression of those proteins in CNS.
For better immunoblotting quantification we performed
dot blot assays. In contrast, Western blot results showithelium as a positive control for the technique. (B) Cerebellar cortex:
er; neuronal cytoplasm was unstained. (C) Thalamus: in the white
nuclear staining, but the cytoplasm was occasionally observed
as also evident in motor neurons. (E) Dorsal horn of a scrapie clinical
ol sheep.
Figure 6 Semiquantitative assessment values of CAPN6, COL1A2, COL3A2, GALA1, MTNR1B and MT1+2 IHC evaluated (from 0:
negative, to 4: staining present at its maximum intensity) in the spinal cord, medulla oblongata, cerebellum, thalamus and
hypothalamus. White bars: control sheep, grey bars: preclinical scrapie-infected and black bars: clinical scrapie-infected sheep. Significant
differences between groups were determined using the Mann Whitney test (**P < 0.05 and *P < 0.1).
Figure 7 MTNR1B immunostaining. (A) In the nucleus of the solitary tract of the medulla oblongata, mild, diffuse neuropil staining was observed
and was stronger in the control animals than in the (B) scrapie-infected animals. (C) In the molecular layer of the cerebellar cortex, a strong signal was
observed in the Purkinje cells and their dendrites (arrowheads). (D) This signal was reduced or absent in the scrapie-infected animals.
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(~70 kDa, ~130 kDa, ~140 kDa, ~8 kDa, ~40 kDa and
~7 kDa for anti-CAPN6, anti-COL1A2, anti-COL3A1,
anti-GALA1, anti-MTNR1B and anti-MT2A, respect-
ively) (Figure 8A). Figure 8 presents the dot images for
the significant results (Figure 8B) and the protein quantifi-
cation results of the six chosen proteins in cSc, Mobl, Cc
and Dien (Figure 8C). The significant changes of protein
expression profiles were in agreement with the variations
observed at the transcript level. These significant differ-
ences were only observed in the clinical scrapie group.
Proteins that presented significant changes in their ex-
pression data in clinical sheep were CAPN6 in the Cc
region, GALA1 in cSc, Cc and Dien, MTNR1B in Mobl
and Dien regions and MT 1 + 2 in Mobl and Cc regions.Figure 8 Western-Blot and dot blot Quantification of protein express
COL1A2, anti-COL3A1, anti-GALA1, anti-MTNR1B and anti-MT2A antibodies
Images of significant results of dot blot quantification (B). Protein expressio
COL3A1, GALA1, MTNR1B and MT2A) in four CNS regions in control (white
sheep in the cervical spinal cord, medulla oblongata, cerebellar cortex and
dots was normalized for Ponceau Red and reported as arbitrary units (a.u.).
groups were analyzed using a Student’s t-test (*P < 0.05 and **P < 0.01).Discussion
The molecular mechanisms of prion disease pathology
are still poorly understood. Our group developed a gen-
omic study assessing the medulla oblongata of sheep
naturally infected with scrapie in the clinical stage [20],
and we studied a set of late phase, scrapie-related genes.
Only one of these genes, MT2A, had previously been
reported to be associated with prion diseases. The other
markers (i.e., CAPN6, COL1A2, COL3A1, GALA1 and
MTNR1B) belong to gene families with a known role in
other neurodegenerative diseases, such as Alzheimer’s or
Parkinson’s disease in humans [21-26,38,39].
Genomic analyses can identify prion-related bio-
markers or candidate targets for new therapies. However,
the results obtained from these studies must be validatedion results in scrapie CNS tissues. Specificity of anti-CAPN6, anti-
in the ovine medulla oblongata, as detected by Western blotting (A).
n profiles of the six scrapie-related proteins (i.e., CAPN6, COL1A2,
bars), preclinical scrapie (grey bars) and clinical scrapie (black bars)
diencephalon using the dot blot assay (C). Density of immunoreactive
Data are expressed as means ± standard error. Differences between
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the disease. Three methodologies have been combined
in the present work, qRT-PCR, immunohistochemistry
and Western/dot blot, to study in depth the possible role
of these markers in prion-induced neuropathology. We
analyzed the gene transcription profiles for the 6 genes
in four CNS regions for a large set of scrapie-infected
sheep (n = 15) in the early and terminal stages of natural
scrapie. We investigated the resulting protein level
changes and the distribution of those proteins in five brain
regions: the cervical spinal cord, medulla oblongata, cere-
bellar cortex, thalamus and hypothalamus.
In order to discard other factors with possible interfe-
rence with other diseases, we selected animals without
any apparent pathology other than scrapie. In addition,
the study design contrasted the amount of infected ani-
mals versus controls, in order to minimize other factors
that could also influence the results.
We present here the first published description of the
CAPN6, COL1A2, COL3A1, GALA1 and MTNR1B im-
munostaining profiles in the adult sheep brain, as well as
their modification upon scrapie infection.
The extracellular matrix (ECM) in the central nervous
system is enriched in proteoglycans (mainly lecticans),
glycoproteins (e.g., tenascin) and hyaluronic acid [40,41].
Collagen I and III molecules, which are abundant in the
ECM of other tissues, are mainly restricted to the vascu-
lar and meningeal compartments of the central nervous
system. In agreement with our earlier work [20], a sig-
nificant decrease in the expression levels of COL1A2
and COL3A1 was observed in the medulla oblongata in
sheep at the clinical stage of scrapie infection.
It has been suggested that changes in cerebrovascular
organs or in the brain blood barrier in response to prion
insult might be occurring in scrapie-infected brains. A
decrease in collagen IV is observed in Multiple System At-
rophy [42], and the reduction of COL6A1 has been
reported in AD [43]. In contrast, the overexpression of the
collagenous type II transmembrane protein (COL25A1)
leads to AD-like pathology and different collagens, inclu-
ding COL1A1 and COL3A1, are induced in multiple scle-
rosis lesions [44]. The expression of COL1A2 transcripts
was strongly downregulated in the medulla oblonga of
scrapie animals both here and in our previous study,
suggesting a role in prion neuropathology since this region
includes a circumventricular organ, the area postrema,
which is enriched in different collagen types and one of
the potential entrances of the prions into the brain [45].
However, neither the immunohistochemical nor the dot
blot analysis confirmed this variation at the protein level.
Expression of the collagen genes (COL1A1, COL1A2, and
COL3A1) is regulated at the transcriptional [46] and post-
transcriptional [47] levels and several RNA-binding pro-
teins may act as stabilizers of the collagen mRNA [48]. Apost-transcriptional regulation could be acting in scrapie
avoiding the loss of collagen proteins in the damaged
brain. Then, our results warn about using these molecules
as potential biomarkers for therapies or preclinical
diagnosis.
Galanin is an inhibitory neuropeptide to which a
neuroprotective role has been attributed [49,50]. However,
increased galanin-1 levels have also been suggested to im-
pair cognitive function [25], and GALA1 has been found
to be overexpressed in Alzheimer’s disease [21,22].
GALA1 is overexpressed in the medulla oblongata of cli-
nical scrapie-infected sheep [20]. In the present study,
GALA1 gene transcription was significantly increased in
all four analyzed brain regions of the clinical scrapie-
infected sheep. Immunoblotting protein quantification re-
vealed nearly the same changes as those observed in gene
transcription. Previous studies have reported neuronal
immunostaining of galanin in the sheep hypothalamus
[51-53], but little to no information was found regarding
glial labeling or other CNS regions. In other species, such
as rats and humans, galanin immunolabeling has been
reported not only in neurons but also in astrocytes and
oligodendrocyte precursors [54]. Galanin is enriched in
the hypothalamus, locus ceruleus, amygdala, bed nucleus
of the stria terminalis, dorsal raphe nucleus, dorsal root
ganglia and cervical spinal cord [49]. The distribution of
galanin immunolabeling observed in sheep was similar to
the descriptions for other species but, in addition to the
known brain regions, we provide the first description of
its presence in the cerebellar cortex. The role of galanin in
neurodegenerative conditions is still unclear and deserves
further attention. Our results show increased galanin ex-
pression in scrapie-infected animals, particularly in the
cerebellar cortex of end-stage animals. It could be hypoth-
esized that a relationship may exist between these changes
in galanin expression and the clinical signs of scrapie, such
as ataxia. In accordance to this, the clinical animals sho-
wing the highest GALA1 protein expression also displayed
the highest scores for PrPSc deposition and spongiosis
(data not shown).
The expression of this protein was not significantly
modified in preclinical sheep avoiding its use as a poten-
tial biomarker for preclinical animals. Nevertheless, once
more, the relevance of this marker in prion pathogenesis
has been confirmed, and GALA1 could be considered a
potential therapeutic target for the treatment of TSE.
Calpains are intracellular, non-lysosomal, calcium-
dependent, cysteine proteases that are involved in proteoly-
sis, apoptotic cell death, necrosis and other physiological
events. Calpain 6 is known to bind and stabilize microtu-
bules in the regulation of microtubule and cytoskeletal
organization during embryonic development [55,56]. In
consequence, CAPN6 expression should be downregulated
after birth, except for placenta and for uterine cell tumors
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immunolabeling restricted to the cytoplasm was expected
in the brain. The described intraglial and neuropile staining
fit well, but the intranuclear staining observed would be
difficult to explain, although previous publications also re-
port nuclear staining, albeit in other tissues [57]. The dif-
ferent forms of calpains localize in a different manner,
whereas μ-calpain is present mainly in the somatodendritic
compartment of neurons, with lower levels in the myeli-
nated axons; m-calpain is located mainly in axons and also
in myelin [58]. The immunolabeling pattern described in
sheep brain in this report was in accordance with those
described for μ-calpain and m-calpain.
In addition to our previous study showing the
overexpression of the Calpain 6 gene in the medulla
oblongata of terminal scrapie [20], other members of the
calpain family have been associated with prion diseases
[59,60] and other neuropathological events, contributing
to Alzheimer’s [61-63] and Parkinson’s [64]. The present
study shows a statistically significant increase in gene
transcription of CAPN6 in all the analyzed brain regions
(i.e., cSc, Mobl, Cc and Dien) of the clinical animals and
in the cSc and Cc of the preclinical animals, which was
in accordance with the increase in calpain expression
throughout the course of the disease in mice [60].
In scrapie affected sheep, astrocytosis is one of the
most common described histopathological events related
with the disease [65]. Thus, glial activation, which is par-
ticularly strong in the Mobl and cSc, might partially ex-
plain the CAPN6 expression changes.
In agreement with the gene transcription results, a
tendency for increased calpain 6 protein immunolabeling
and immunoblotting was observed in the majority of the
regions analyzed in scrapie-infected animals, being par-
ticularly significant in the cSc and Cc of clinical cases.
Further attention should be given to the involvement of
calpain 6 in the pathogenesis of scrapie because the
neuropil immunostaining was increased in clinical scra-
pie animals, particularly in the dorsal horn of the spinal
cord. This region includes sensory pathways (Substantia
gelatinosa and proprius nuclei are craneally connected
with the spinal tract of the trigeminal nerve) and is
strongly involved in nociception (tactile information),
thus changes at this level could be related to some of the
scrapie clinical signs, such as hyperesthesia, pruritus and
scratch response. Our results suggest that Calpain 6 may
be a potential therapeutic target in prion diseases as they
are in Parkinson’s disease [66]. This suggestion is sup-
ported by other studies describing that calpain-mediated
endoproteolytic cleavage of PrPSc may be an important
event in prion propagation [67]. However, the possible
involvement of calpain-like activity in the normal pro-
cessing of PrPC [68] has to be considered in any further
therapeutic study focused on a possible regulation of thistarget. In addition, since this protein is overexpressed in
the Sc and Cc of preclinical individuals, we could
propose it as a good candidate diagnostic biomarker for
scrapie.
The indoleamine melatonin (N-acetyl-5-methoxy-
tryptamine) is synthesized in the pinealocytes, located in
the pineal gland (Epiphysis cerebri) of the mammalian
brain. In addition to its role as a chronobiotic in mam-
mals, melatonin is an antioxidant and an effective pro-
tector of mitochondrial bioenergetics [69]. Melatonin
protects from Aβ toxicity, especially at the mitochon-
drial level [70,71], and is used as an antioxidant in AD
patients [72]. All known actions and effects of melatonin
are mediated by membrane receptors on the cell surface
(i.e., MTNR1A and MTNR1B) [73,74]. Expression of the
human MTNR1B (also called MT2 receptor) protein
was demonstrated in the hippocampus and cortex by
immunohistochemical studies, reporting decreased in-
tensity of the MTNR1B staining in AD cases [75,76]. In
our study, the expression of the MTNR1B gene was sig-
nificantly downregulated in the Mobl, Cc and Dien re-
gions of clinical sheep and in the Cc region of the
preclinical scrapie-infected animals. This finding was
consistent with the significantly lower MTNR1B protein
expression in Mobl and Dien in clinical animals,
detected by dot blot quantification, and the significantly
lower score of MTNR1B immunostaining in the cerebel-
lum of clinical and preclinical animals. Our results
strongly suggest the contribution of the melatonin re-
ceptor in ovine classical scrapie pathology, even in the
early phase of the disease and in different brain regions;
therefore, melatonin may be a good candidate target for
future prion disease therapies. In accordance with our
suggestion, a recent report has shown that melatonin-
induced autophagy protects against prion protein-
mediated neurotoxicity [77].
MT 1 and 2 are cell stress-related genes which are
coordinately regulated by metals, glucocorticoids and
inflammatory stress signals [78]. In addition to the
overexpression previously reported for MT2A in the me-
dulla oblongata during clinical scrapie [20], a significant
over expression of MT2A was observed in the four CNS
regions analyzed in clinical scrapie and in the cSc and
Cc of the preclinical scrapie-infected animals. The up-
regulation of MT2 was confirmed by immunohisto-
chemistry and immunoblotting assay. These results were
in agreement with the previous descriptions of metallo-
thioneins in experimental and natural scrapie and other
TSE [38,39,79-81]. Those reports suggest that oxidative
stress, most likely a consequence of the glial activation
elicited by the PrPSc deposition, is a pivotal mechanism
in prion neurodegeneration pathogenesis. In addition,
the confirmed upregulation of metallothioneins during
preclinical natural scrapie suggests that these proteins
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biomarkers.
In summary, we present here the gene transcription
data and immunohistochemical protein distributions for
CAPN6, COL1A2, COL3A1, GALA1, MTNR1B and
MT2A in various regions of the CNS based on a large
set of sheep with naturally occurring classical scrapie, in-
cluding both the clinical and preclinical stages of the
disease. The CNS distribution of five of these proteins,
as well as their correlation with the gene transcription, is
reported here for the first time. The increased expres-
sion of CAPN6, GALA1 and MT2A in most of the brain
regions analyzed suggests a potential role of these genes
in early and terminal scrapie pathogenesis, which is fur-
ther supported by immunohistochemical and immuno-
blotting evidence. These proteins would be potential
biomarkers for preclinical diagnosis of scrapie because
they have been detected in young animals, however, fur-
ther analysis studying the expression of these markers in
peripheral tissues is necessary. Also these markers could
be considered potential therapeutic targets for prion di-
seases, since they are used in other neurodegenerative
diseases. The down-regulation of MTNR1B argues in
favor of a loss of the neuroprotection produced by mela-
tonin, particularly in the cerebellar cortex region. These
genes can be considered good candidate targets for the
development of future prion therapies.
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